WO1997001640A3 - Vaccines against hepatitis c - Google Patents

Vaccines against hepatitis c Download PDF

Info

Publication number
WO1997001640A3
WO1997001640A3 PCT/EP1996/002764 EP9602764W WO9701640A3 WO 1997001640 A3 WO1997001640 A3 WO 1997001640A3 EP 9602764 W EP9602764 W EP 9602764W WO 9701640 A3 WO9701640 A3 WO 9701640A3
Authority
WO
WIPO (PCT)
Prior art keywords
oil
hepatitis
vaccines against
against hepatitis
water emulsion
Prior art date
Application number
PCT/EP1996/002764
Other languages
French (fr)
Other versions
WO1997001640A2 (en
Inventor
Silva Teresa Cabezon
Patricia Marie Momin
Nathalie Marie-Josephe Garcon
Original Assignee
Smithkline Beecham Biolog
Silva Teresa Cabezon
Patricia Marie Momin
Garcon Nathalie Marie Josephe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog, Silva Teresa Cabezon, Patricia Marie Momin, Garcon Nathalie Marie Josephe filed Critical Smithkline Beecham Biolog
Priority to JP9504167A priority Critical patent/JPH11508769A/en
Priority to EP96922029A priority patent/EP0835318A2/en
Priority to BR9609258A priority patent/BR9609258A/en
Priority to AU63049/96A priority patent/AU6304996A/en
Priority to PL96324906A priority patent/PL324906A1/en
Publication of WO1997001640A2 publication Critical patent/WO1997001640A2/en
Publication of WO1997001640A3 publication Critical patent/WO1997001640A3/en
Priority to NO976060A priority patent/NO976060L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

A vaccine composition comprises QS21,3 De-O-acylated monophosphoryl lipid A (3D-MPL), an oil in water emulsion, wherein the oil in water emulsion has the following composition: a metabolisible oil, such as squalene, alpha tocopherol and tween 80, and at least one immunogen selected from the group consisting of (a) a hepatitis C virus core protein or an immunogenic derivative thereof, and (b) a hepatitis C virus envelope protein or an immunogenic derivative thereof.
PCT/EP1996/002764 1995-06-29 1996-06-20 Vaccines against hepatitis c WO1997001640A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP9504167A JPH11508769A (en) 1995-06-29 1996-06-20 Vaccine against hepatitis C
EP96922029A EP0835318A2 (en) 1995-06-29 1996-06-20 Vaccines against hepatitis c
BR9609258A BR9609258A (en) 1995-06-29 1996-06-20 Hepatitis C vaccines
AU63049/96A AU6304996A (en) 1995-06-29 1996-06-20 Vaccines against hepatitis c
PL96324906A PL324906A1 (en) 1995-06-29 1996-06-20 Vaccines against viral hepatitis of c type
NO976060A NO976060L (en) 1995-06-29 1997-12-23 Vaccines against hepatitis C

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9513261.9 1995-06-29
GBGB9513261.9A GB9513261D0 (en) 1995-06-29 1995-06-29 Vaccines

Publications (2)

Publication Number Publication Date
WO1997001640A2 WO1997001640A2 (en) 1997-01-16
WO1997001640A3 true WO1997001640A3 (en) 1997-05-15

Family

ID=10776867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002764 WO1997001640A2 (en) 1995-06-29 1996-06-20 Vaccines against hepatitis c

Country Status (15)

Country Link
EP (1) EP0835318A2 (en)
JP (1) JPH11508769A (en)
KR (1) KR19990028505A (en)
AU (1) AU6304996A (en)
BR (1) BR9609258A (en)
CA (1) CA2222456A1 (en)
CZ (1) CZ422397A3 (en)
GB (1) GB9513261D0 (en)
HU (1) HUP9901901A3 (en)
IL (1) IL122589A0 (en)
NO (1) NO976060L (en)
PL (1) PL324906A1 (en)
TR (1) TR199701713T1 (en)
WO (1) WO1997001640A2 (en)
ZA (1) ZA965459B (en)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283012T3 (en) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. HELICOBACTER PYLORI BACTERIOFERRITINE.
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
AT405939B (en) * 1997-02-24 1999-12-27 Immuno Ag METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO2000011186A1 (en) * 1998-08-21 2000-03-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified hcv peptide vaccines
ATE357252T1 (en) 1998-10-16 2007-04-15 Glaxosmithkline Biolog Sa ADJUVANCE SYSTEMS AND VACCINES
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
NZ518999A (en) * 1999-11-19 2002-12-20 Csl Ltd Vaccine compositions
MXPA03003690A (en) 2000-10-27 2004-05-05 Chiron Spa Nucleic acids and proteins from streptococcus groups a b.
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
AU2002249253A1 (en) * 2002-03-04 2002-07-08 Zagyansky, Yuly Universal antimicrobial treatment
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2608048T3 (en) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
DK1961426T3 (en) 2003-10-02 2011-08-08 Novartis Ag Combination vaccines against meningitis
DE202005022108U1 (en) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza virus vaccines
RU2379052C2 (en) 2004-04-30 2010-01-20 Чирон С.Р.Л. Meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
JP2008504292A (en) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Immune enhancement compounds
EP1784211A4 (en) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (en) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CN101203529A (en) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2009511636A (en) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Mucosal and systemic immunity with alphavirus replicon particles
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
RU2471497C2 (en) 2007-09-12 2013-01-10 Новартис Аг Mutant antigens gas57 and gas57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
PE20110891A1 (en) 2008-12-09 2011-12-23 Pfizer Vaccines Llc IGE CH3 PEPTIDE VACCINE
CA2749367A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
KR101450958B1 (en) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 Pneumococcal vaccine and uses therof
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
MX2012000734A (en) 2009-07-16 2012-01-27 Novartis Ag Detoxified escherichia coli immunogens.
CN102596236B (en) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 Antigenic Tau peptides and uses thereof
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
BR112012008338A2 (en) 2009-09-10 2019-09-24 Novartis Ag combination of vaccines against respiratory tract diseases.
KR101746880B1 (en) * 2009-09-10 2017-06-14 메리얼 인코포레이티드 New vaccine formulations comprising saponin-containing adjuvants
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CN102724988B (en) 2009-09-30 2014-09-10 诺华股份有限公司 Expression of meningococcal fHBP polypeptides
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
MX337070B (en) 2009-12-22 2016-02-11 Celldex Therapeutics Inc Vaccine compositions.
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
ES2910199T3 (en) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Factor H-binding proteins (fHbp) with altered properties and methods of using them
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127316A1 (en) 2010-04-07 2011-10-13 Novartis Ag Method for generating a parvovirus b19 virus-like particle
CN102933267B (en) 2010-05-28 2015-05-27 泰特里斯在线公司 Interactive hybrid asynchronous computer game infrastructure
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP3153578A1 (en) 2010-07-06 2017-04-12 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2819416C (en) 2010-12-02 2019-04-30 Bionor Immuno As Peptide scaffold design
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
EP2736921B1 (en) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP2755994A2 (en) 2011-09-14 2014-07-23 Novartis AG Escherichia coli vaccine combination
CN103917245B (en) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 Method for preparing glycoprotein glycoconjugate
SG11201402375VA (en) 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
RU2014138418A (en) 2012-02-24 2016-04-10 Новартис Аг PROTEINS OF SAWS AND COMPOSITIONS
AU2013254751B2 (en) 2012-04-26 2017-12-14 Glaxosmithkline Biologicals S.A. Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
PE20142406A1 (en) 2012-05-04 2015-01-23 Pfizer ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES
MX2014014067A (en) 2012-05-22 2015-02-04 Novartis Ag Meningococcus serogroup x conjugate.
MX2014014683A (en) 2012-06-06 2015-02-24 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants.
CN104602702B (en) 2012-09-18 2021-08-27 葛兰素史密丝克莱恩生物有限公司 Outer membrane vesicles
CN105307684A (en) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 Nonlinear saccharide conjugates
JP6266000B2 (en) 2012-10-03 2018-01-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
RS56886B1 (en) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
EP3096785B1 (en) 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
EP4074726A3 (en) 2014-07-23 2022-11-23 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
HRP20230416T1 (en) 2015-01-15 2023-07-07 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA2986494A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
CN108367063A (en) 2015-07-21 2018-08-03 辉瑞公司 Include the immunogenic composition and its kit and purposes of conjugated Capsular saccharide antigen
JP6884145B2 (en) 2015-11-20 2021-06-09 ファイザー・インク Immunogenic composition for use in Streptococcus pneumoniae vaccine
CA2954892A1 (en) 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
MX2019008564A (en) 2017-01-20 2019-09-19 Pfizer Immunogenic compositions for use in pneumococcal vaccines.
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
WO2020039033A1 (en) 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4051696A1 (en) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
JP2021132644A (en) 2020-02-21 2021-09-13 ファイザー・インク Purification of saccharide
JP2023514697A (en) 2020-02-23 2023-04-07 ファイザー・インク E. coli composition and method
KR20230096033A (en) 2020-10-27 2023-06-29 화이자 인코포레이티드 Escherichia coli composition and method thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20220265805A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202304503A (en) 2021-05-28 2023-02-01 美商輝瑞大藥廠 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472207A2 (en) * 1990-08-24 1992-02-26 Abbott Laboratories Hepatitis C assay utilizing recombinant antigens
DE4041304A1 (en) * 1990-12-21 1992-06-25 Mikrogen Molekularbiol Entw POLYPEPTIDES DERIVED FROM STRUCTURAL PROTEINS OF HEPATITIS C-VIRUS, TEST KITS CONTAINING THESE POLYPEPTIDES AND VACCINE AGAINST INFECTIONS FROM HEPATITIS C VIRUSES
WO1993000365A2 (en) * 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
WO1993019780A1 (en) * 1992-03-27 1993-10-14 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a
WO1994000153A1 (en) * 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
JPH06279500A (en) * 1992-09-30 1994-10-04 Imuno Japan:Kk Hbc fused protein particle and its production
WO1995017210A1 (en) * 1993-12-23 1995-06-29 Smithkline Beecham Biologicals (S.A.) Vaccines

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472207A2 (en) * 1990-08-24 1992-02-26 Abbott Laboratories Hepatitis C assay utilizing recombinant antigens
DE4041304A1 (en) * 1990-12-21 1992-06-25 Mikrogen Molekularbiol Entw POLYPEPTIDES DERIVED FROM STRUCTURAL PROTEINS OF HEPATITIS C-VIRUS, TEST KITS CONTAINING THESE POLYPEPTIDES AND VACCINE AGAINST INFECTIONS FROM HEPATITIS C VIRUSES
WO1993000365A2 (en) * 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
WO1993019780A1 (en) * 1992-03-27 1993-10-14 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a
WO1994000153A1 (en) * 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
JPH06279500A (en) * 1992-09-30 1994-10-04 Imuno Japan:Kk Hbc fused protein particle and its production
WO1995017210A1 (en) * 1993-12-23 1995-06-29 Smithkline Beecham Biologicals (S.A.) Vaccines
WO1995017209A1 (en) * 1993-12-23 1995-06-29 Smithkline Beecham Biologicals (S.A.) Vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9444, Derwent World Patents Index; Class B04, AN 94-354772, XP002028489 *

Also Published As

Publication number Publication date
BR9609258A (en) 1999-05-11
IL122589A0 (en) 1998-06-15
ZA965459B (en) 1997-04-01
JPH11508769A (en) 1999-08-03
KR19990028505A (en) 1999-04-15
HUP9901901A3 (en) 2000-03-28
TR199701713T1 (en) 1998-05-21
WO1997001640A2 (en) 1997-01-16
NO976060D0 (en) 1997-12-23
CZ422397A3 (en) 1998-06-17
HUP9901901A2 (en) 1999-09-28
GB9513261D0 (en) 1995-09-06
PL324906A1 (en) 1998-06-22
NO976060L (en) 1998-02-17
MX9710523A (en) 1998-09-30
AU6304996A (en) 1997-01-30
EP0835318A2 (en) 1998-04-15
CA2222456A1 (en) 1997-01-16

Similar Documents

Publication Publication Date Title
WO1997001640A3 (en) Vaccines against hepatitis c
CA2302554A1 (en) Oil in water emulsions containing saponins
MY134811A (en) A vaccine composition comprising an antigen, a saponin and a sterol
HUP9903169A3 (en) Low pathogenicity prrs live virus vaccines and methods of preparation thereof
EP1946773A3 (en) Improved saponin adjuvant compositions and methods relating thereto
AU6803198A (en) Vaccines
DK0957935T3 (en) Chlamydia vaccines and immunogenic preparations containing an outer membrane antigen and method of preparation thereof
EP1170016A3 (en) Urease-based vaccine against helicobacter infection
GB9626484D0 (en) Helicobacter pylori antigenic protein preparation and immunoassays
CA2132547A1 (en) Vaccines Containing Non-Ionic Surfactant Vesicles
AU6093296A (en) Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0745387A3 (en) Adjuvants for viral vaccines
ZA936629B (en) Potentiation of immunogenic response
DK0792165T3 (en) Immunogenic Preparations
NO912825D0 (en) PROCEDURE FOR THE PREPARATION OF COCONJUGATE VACCINES INCLUDING IMMUNOGENIC PROTEIN, HIV RELATED PEPTIDES AND ANIONIC GROUPS.
DE3473825D1 (en) Method of preparing adjuvanted live vaccines and adjuvanted live vaccines thus obtained
CA2190344A1 (en) Quillaja saponin adjuvant and vaccine formulation containing same
CA2099707A1 (en) Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
CA2352563A1 (en) Method to produce inactivated w/o emulsion adjuvanted vaccines
CA2216410A1 (en) Improved inactivated vaccines
WO2002038176A3 (en) Immunogenic compositions comprising liver stage malarial antigens
WO2002009749A3 (en) Respiratory syncytial virus vaccine
WO2000069458A3 (en) Adjuvant combinations for immunization composition and vaccines
CA2112225A1 (en) Attenuated revertant serotype 1 marek's disease vaccine
WO2002024147A3 (en) Avian pneumovirus vaccine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96195150.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 311683

Country of ref document: NZ

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996922029

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2222456

Country of ref document: CA

Ref document number: 2222456

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/010523

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1997 504167

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 97/01713

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1019970709823

Country of ref document: KR

Ref document number: PV1997-4223

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1996922029

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1997-4223

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019970709823

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1997-4223

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1996922029

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019970709823

Country of ref document: KR